We are live on ! Find out more
AKYA

Akoya BioSciences

Delisted

AKYA was delisted on the 7th of July, 2025.

58 hedge funds and large institutions have $16.3M invested in Akoya BioSciences in 2025 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.14% less ownership

Funds ownership: 25.24%25.1% (-0.14%)

9% less funds holding

Funds holding: 6458 (-6)

23% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 26

44% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 18

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

50% less capital invested

Capital invested by funds: $32.8M → $16.3M (-$16.5M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $25K

Holders
58
Holders Change
-6
Holders Change %
-9.38%
% of All Funds
0.76%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
20
Increased
10
Reduced
18
Closed
26
Calls
Puts
$25K
Net Calls
-$25K
Net Calls Change
-$99K
Name Holding Trade Value Shares
Change
Change in
Stake
BWLSA
1
Blue Water Life Science Advisors
California
$6.11M
OBAM
2
ODDO BHF Asset Management
France
$2.46M +$2.28M +1,892,855 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$1.55M -$233K -194,073 -14%
PAPAIJV
4
Paragon Associates & Paragon Associates II Joint Venture
Texas
$872K
TC
5
Trium Capital
United Kingdom
$787K +$728K +605,496 New
BlackRock
6
BlackRock
New York
$649K -$1.34M -1,112,492 -69%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$319K -$387K -321,317 -57%
PCA
8
Peddock Capital Advisors
Massachusetts
$305K
ECM
9
ExodusPoint Capital Management
New York
$267K +$247K +205,320 New
Jane Street
10
Jane Street
New York
$233K +$198K +164,244 +1,085%
State Street
11
State Street
Massachusetts
$231K -$381K -316,343 -64%
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$230K +$173K +143,431 +428%
Goldman Sachs
13
Goldman Sachs
New York
$225K +$88.6K +73,661 +74%
UBS Group
14
UBS Group
Switzerland
$225K -$131K -108,825 -39%
CIEC
15
Crédit Industriel et Commercial
France
$221K
JP Morgan Chase
16
JP Morgan Chase
New York
$182K -$327K -271,638 -66%
JC
17
JBF Capital
Colorado
$155K +$144K +119,508 New
Citadel Advisors
18
Citadel Advisors
Florida
$131K +$121K +100,467 New
CL
19
CSS LLC
Illinois
$125K +$116K +96,011 New
Millennium Management
20
Millennium Management
New York
$119K -$26.1K -21,669 -19%
Northern Trust
21
Northern Trust
Illinois
$109K -$178K -147,730 -64%
Morgan Stanley
22
Morgan Stanley
New York
$108K -$36.9K -30,679 -27%
Marshall Wace
23
Marshall Wace
United Kingdom
$96K +$88.9K +73,881 New
Qube Research & Technologies (QRT)
24
Qube Research & Technologies (QRT)
United Kingdom
$88.5K +$81.9K +68,110 New
ZIC
25
ZWJ Investment Counsel
Georgia
$62.4K

AKYA Hedge Fund Activity: Q2 2025 in Review

58 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q2 2025, worth a combined $16.3M — down 50% from $32.8M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of AKYA and 20 opened new positions — a net loss of 6 holders — while 18 trimmed existing stakes and 10 added.

The largest buyer was ODDO BHF Asset Management, opening a new position worth an estimated $2.28M. The largest seller was Nuveen, exiting entirely with an estimated $15.9M sold.

  • 58 institutional investors held Akoya BioSciences (AKYA) as of Q2 2025, down from 64 in Q1 2025.
  • Funds reported $16.3M of Akoya BioSciences stock for Q2 2025, down 50% quarter-over-quarter.
  • 20 funds opened new Akoya BioSciences positions in Q2 2025 and 26 closed out, a net change of -6 holders.
  • The largest Akoya BioSciences buyer in Q2 2025 was ODDO BHF Asset Management, an estimated $2.28M added.
  • The largest Akoya BioSciences seller in Q2 2025 was Nuveen, an estimated $15.9M sold.

Based on aggregated 13F filings for Q2 2025.